Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Clinical trial NCT05296278 · UNKNOWN

Trial details

NCT number: NCT05296278
Sponsor: Hunan Province Tumor Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2023-12-25
Primary completion: 2025-12-10
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.